Close

Form 8-K StHealth Capital Investm For: Aug 15

August 16, 2022 12:04 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
 

 UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

FORM 8-K 

 

CURRENT REPORT 

PURSUANT TO SECTION 13 OR 15(d) 

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): August 15, 2022

 

StHealth Capital Investment Corporation

(Exact Name of Registrant as Specified in Its Charter) 

 

Maryland

(State of other jurisdiction of incorporation or organization)

814-01137

(Commission File Number)

47-1709055

(I.R.S. Employer Identification No.)

 

 

  

5050 Quorum Drive, Suite 700 #9629

Dallas, TX 75254

(Address of principal executive offices)

 

 
 

212-671-0078

(Registrant’s telephone number, including area code)

 

680 Fifth Ave., 21st Floor, New York, NY 10019

(Former name or former address, if changed since last report) 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading symbol(s) Name of each exchange
on which registered
Common stock, par value $0.001 per share N/A Not registered on any exchange at this time
Preferred stock, par value $0.001 per share N/A Not registered on any exchange at this time

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(a) Resignation of Chief Compliance officer

 

On August 1, 2022, Manoj Pombra (Tito), Chief Compliance Officer, submitted a written notification of his resignation to the Registrant’s board of directors, pursuant to which he resigned his executive position as Chief Compliance Officer of the Registrant, effective as of the close of business on August 15, 2022. The resignation was accepted by the Registrant’s board of directors.

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 15, 2022

  StHealth Capital Investment Corporation
   
  /s/ Jeff Davi  
  Jeff Davi
  Chairman of the Board

 

 

 



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings